Monitor for any Form 4 filings from Ting Yang, Lina Deng, or David Lazar indicating share sales. The effective shelf removes the last procedural hurdle to insider selling, which could accelerate price declines. Given the company's lack of active programs and going-concern warning, any selling pressure is likely to be met with limited buying interest.
Price Chart
Executive Summary
Indaptus Therapeutics' S-3 registration statement (File No. 333-297088) became effective on July 17, 2026, enabling selling stockholders Ting Yang, Lina Deng, and David Lazar to resell up to 18,864,000 shares (~14.2% of outstanding). The company receives no proceeds and has discontinued all clinical development, with its auditor expressing substantial doubt about going concern. This effectiveness removes the final procedural barrier to insider selling, adding immediate overhang to a stock already under severe fundamental distress.
Key Facts
- S-3 shelf became effective on 2026-07-17, allowing resale of up to 18,864,000 shares by selling stockholders.
- Company discontinued all clinical development of lead candidate Decoy20 and has no active programs.
- Auditor has expressed substantial doubt about Indaptus' ability to continue as a going concern.
- Indaptus will not receive any proceeds from the resale of shares under this shelf.
- The shelf was filed on 2026-06-26 and the EFFECT notice confirms effectiveness 24 days later.
Financial Impact
Potential dilution of ~14.2% of outstanding shares via resale; no proceeds to company. Company has no revenue and is burning cash with going-concern risk.
Risk Factors
- Immediate selling by insider stockholders could drive the stock lower.
- No active pipeline or revenue to support valuation; going-concern risk may materialize.
- Low liquidity may amplify price moves on any selling volume.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-002348 |
| Document: 9999999995-26-002348-index.html | 9999999995-26-002348 |
| Document: 9999999995-26-002348.txt | 9999999995-26-002348 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $2.56 $3.93 | ▼ −53.52% | ▼ −52.89% | $2.33 (+8.98%) |
Sep 4, 2026 27d ago | 424B5 | $1.85 $3.64 | ▼ −96.76% | ▼ −97.88% | $2.33 (−25.95%) |
Sep 1, 2026 4w ago | 8-K | $1.13 $2.08 | ▼ −84.07% | ▼ −83.99% | $2.33 (−106.19%) |
Aug 26, 2026 5w ago | EFFECT | $1.14 $1.17 | ▼ −2.63% | ▼ −2.75% | $2.33 (−104.39%) |
Aug 17, 2026 6w ago | S-3 | $0.9361 $1.10 | ▼ −16.97% | ▼ −17.18% | $2.33 (−148.91%) |
Aug 13, 2026 7w ago | 8-K | $1.06 $1.38 | ▲ +30.19% | ▲ +32.15% | $2.33 (+119.81%) |
Jul 20, 2026 10w ago | EFFECT | $2.46 $2.61 | ▼ −6.10% | ▼ −6.52% | $2.33 (+5.28%) |
Jun 26, 2026 13w ago | S-3 | $3.06 $2.85 | ▲ +6.86% | ▲ +8.25% | $2.33 (+23.86%) |
Jun 24, 2026 14w ago | 8-K | $3.26 $2.94 | ▲ +9.82% | ▲ +11.38% | $2.33 (+28.53%) |
May 15, 2026 20w ago | 8-K | $1.59 $1.22 | ▲ +23.27% | ▲ +24.23% | $2.33 (−46.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access